Method of treating degenerative-dystrophic diseases of locomotor apparatus

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

 

The proposed method for the treatment of degenerative-dystrophic diseases (RSD) of bone and muscle and joint system of the body relates to medicine, namely to orthopedics and traumatology, and can be used for conservative treatment of deforming arthrosis of the joints, osteoarthritis of the spine and intervertebral uncomplicated hernias, the upper periartropatii, insertitem, tendonitis, burstow degenerative or traumatic origin, during rehabilitation after injury or trauma and orthopedic surgeries on joints and limbs.

The starting point in the conservative therapy of degenerative diseases of musculoskeletal system (ODE) is traditionally considered to be the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroid. The history of the discovery of these funds begins with the use of salicylates (1864). Intra-articular, intrabursal, paraartikulyarnye, paravertebral injectable analgesia with the use of corticosteroids used since 1950, when the Y. W. Thorn (Boston) was the first to introduce intra-articular patient with rheumatoid synovitis in the knee joint 10 ml hydrocortisone and immediately received a positive result. A pronounced positive effect of intra-articular injections of glucocorticoids noted in 1951 J. L. Hollnder (Philadelphia) introducing acetate hydrocortisone in knee joints of patients with rheumatoid arthritis and osteoarthritis [Nasonov E. L., Chicherova N. In., Kovalev C. Y. Local treatment with glucocorticoids // Russian medical journal. 1999. So 7. No. 8. S. 385-391; Dixon A. S. J., J. Graber Local Injection Therapy in Rheumatic Diseases. Basle: Eular Publishers, 1983. P. 181]. Alcohol-novocaine blockade, which was the idea of a Russian scientist, Professor, head of Department of traumatology and orthopedics of the State Central Institute of advanced training of doctors (the Central Institute of postgraduate education) M. O. Friedland in 1938, was successfully used during the great Patriotic war with broken ribs, extremities [M. O. Friedland and others, "Alcohol-novocaine blockade as a method of combating muscle retraction (muscle contraction.K.) fractures of long tubular bones, 1938]. 17 years later, in 1955 M. O. Friedland wrote about the effectiveness of alcohol-procaine blockade of the joint in the period of exacerbation of osteoarthritis.

Extracorporeal shock wave therapy (of extracorporeal) as an independent approach to the treatment of pathology ODE and limb injuries was first successfully applied by domestic doctors in 1988 [Valchanov V. et al., 1991]. The end of XX - beginning of XXI centuries was early experimental use of extracorporeal and identification of their useful properties and effects, namely analgesic effect, activation of microcirculation and neoangiogenesis, the stimulation meth is politeski processes, reduced severity of fibro-sclerotic changes, anti-inflammatory and antibacterial action [Garilevich B. A., 1992; Valchanov V. et al., 1991; Garilevich B. A., 1992; Mironov SP. et al., 1999; Nikolaev, A. P. et al., 1999; Egorova E. A., 1999; Garilevich B. A., Olefir Y. C., 2004; Siebert W., Bush, M., 1997; von Eiff C. et al., 2000; Haake M. et al., 2002; Wess O., 2003; Thiele R., W. Schaden, 2003; Yeung-Jen Chen et al., 2004; Gerdesmeyer L. et al., 2004; Gollwitzer H. et al., 2004; Takahiro Nishida et al., 2004; Gerdesmeyer L. et al., 2005 G. Haupt, 1997; Valchanov V. et al., 1991; Loshe-Busch H. et al., 1997; Siebert W., Bush, M., 1997]. Proved its effectiveness in the treatment of Peyronie's disease, neuromuscular dysfunction in children with spastic cerebral palsy [Loshe-Busch N. et al., 1997; Siebert W., Bush, M., 1997]. Recent studies have shown long-term use of extracorporeal in cardiology for the treatment of patients with ischemic heart disease [Takahiro Nishida et al., 2004; Uwatoku T., Ito K., Abe K. et al., 2007]. In Russia the method of extracorporeal have been widely used since the early 2000-ies. Of extracorporeal today has many points of application in various fields of medicine: trauma and Orthopaedics, urology, neurology, vertebrology, reabilitology, cardiology and cosmetology. At carrying out of extracorporeal patients with pathology ODE mode of exposure is gradually increased to eliminate the uncomfortable sensations and temporary increase of pain. Pick it up individually, focusing on the peculiarities of the course of disease is, stage processes, the presence of comorbidity and features of the patient's body.

According to the world health organization, RSD ODE occurs in 10-15% of the adult population, with 10 times more often in women than in men, mostly aged 45-55 years. Among the causes temporary disability, the share of diseases of the musculoskeletal system have to 8.6%, according to statistics in the USA up to 7% of the population in Sweden is up to 6% of the population in the countries of the former USSR to 6.43% of the population. With all this 51.4% of the affected RSD ODE become totally disabled [Traumatology and Orthopaedics, edited by N. Kornilov.In., St. Petersburg: "Hippocrates", 2004, 1 T. p. 98; Benevolensky L. I., Brzozowski M. M. Epidemiology of rheumatic diseases. - M.: Medicine, 1988. - 237 S. - ISBN 5-225-01653-7].

The unsatisfactory results of conservative treatment ODE, as a rule, are explained by the stage, degree and severity of lesions or other anatomical regions and their number, the patient's age and presence of comorbidity, aggravating traditional treatment, the individual characteristics of the organism and the degree of susceptibility to drugs and visiomodeler.

Despite a considerable number of ways to treat these pathologies, the results do not always meet the patient and physician, that is as a consequence of conservative treatment are: insufficient relief of pain and early disease recurrence, reduced quality of life due to loss of functionality, support ability of the limb up to the full off and the impossibility of self-service patient, incomplete and long-term medical and social rehabilitation, and sometimes the absence of the latter, the rapid progression of the disease leading to permanent disability of the patients.

The closest analogue to the proposed method of treatment of various pathologies OSTEOARTHRITIS is intramuscular, intra - and periarticular introduction and oral application of the following dosage forms: NSAIDs and analgesics, protective agents and corticosteroids, vitamins and funds the replacement of synovial fluid, and method of extracorporeal and other physiotherapy ["Orthopaedics National leadership," edited by S. P. Mironov, D. P. Nyquist, M.: "GEOTAR-Media", 2008, pp. 448-452].

Disadvantages: insufficient relief of pain, a shorter period of remission, a significant period of the rehabilitation period and the period of incapacity, the victim of the scheme held by conservative therapy does not always take into account the individual characteristics, the susceptibility of the organism of the patient and the severity of the disease.

Objectives: the immediate direct impact on the primary lesion is the target organ; the achievement of optimal and sufficient medical end of the ation of drugs into the affected organ, eliminating the need to systematically appointed by pharmacological means and prevents the risk of side effects when they are applied; the inclusion in therapy an important part of rehabilitation RSD - concurrent sessions of extracorporeal on the area affected of the hearth and the segments adjacent to it, which involves the most comprehensive and complete treatment ODE, the violation of which is the cause of the disability; reducing the cost and time of complex therapy with the maximum acceptable rehabilitation and end positive effect.

The method of treatment of RSD ODE is that injection in the region of the pathologically changed hearth introduce 16-21 ml of a solution consisting of drugs: glucosamine sulfate Dona - 3.0 ml, and chondroitin sulfate Chondrogard", or "Mucosal", or "Chongryon" - 2.0 ml, and Alflutop" - 2.0 ml and Actovegin - 4,0-5,0 ml, and corticosteroids - "Depo-medrol" - 1,0-2,0 ml at a concentration of 40 mg/ml, or "Diprospan" - 1,0-2,0 ml at a concentration of 7 mg/ml, or Metypred" - 1,0-2,0 ml at a concentration of 62.5 mg/ml, and vitamins B1, B6, B12 - Combilift" - 2.0 ml, or Milgamma" - 2.0 ml, or Neurobion" - 3.0 ml, and 95% ethyl alcohol or 70% - 2,0-4,0 ml, and immediately after that the area of the pathological lesion and adjacent thereto segments is performed with the ANS shock wave therapy in the following mode: pressure - 1,2-4,0 bar, frequency - 7-12 Hz, number of shock - 8000-14000 within 20-40 minutes, and complex procedures carried out course 1-6 times at intervals of 7-10 days.

The technical result of the proposals is minimal invasiveness and reduce the time held adjuvant therapy, ensuring reliable access of drugs to the target organ and scope them in the pathological focus, minimizing the risk of side effects with the introduction of drug injection blockages, increasing medical and social rehabilitation and quality of life of the patient, reducing the number of relapses with increased remission of the disease until the formation of stable remission.

The method is tested for five years in more than 300 patients. This confirmed the above technical result.

The control group was selected 168 patients with the most severe symptoms and stage of the illness. The average age of 49.3 years. 126 patients (75%) were of working age. 63 men (50%), 63 were women (50%). Data the results of the comprehensive therapy and baseline are shown in table 1, 2, 3.

Table 1
Comparative analysis of the result is the proposed method of treatment and the base (nearest equivalent)
Indicators/ Signs on a scaleThe control group (the proposed method of treatment - the author's comprehensive inside, periarticular, vnutrikvartalny, paravertebral blockade and of extracorporeal)The main group of agents, protective agents, ointments, stimulator of tissue repair - alflutop intramuscularly scheme)
Gonarthrosis 2-3 tbsp., aggravation. Chronic synovitis. Severe arthralgia.Osteochondrosis, spondylosis, spondylarthrosis, protrusion of intervertebral discs. Expressed lumboischialgia.Gonarthrosis 1 tbsp., exacerbationOsteochondrosis, spondylosis, spondylarthrosis. Chronically recur; its course.
The pain intensity before therapy++++++++++++++++
Pain, symptoms of relapse after treatment:
After 1 year- -++++
After 3 years--++++
After 5 years++++++++++
Complications during therapy:
Exacerbation of chronic diseases of the gastrointestinal tract, and others;--+++++
Temporary worsening of the underlying disease for the entire period of the treatment++--
Quality of life after treatment++++++++++
The annual financial cost of treatment+++++ +++

Table 2
Indicators/ Signs on a scaleThe control group (the proposed method of treatment - the author's comprehensive inside, periarticular, vnutrikvartalny, paravertebral blockade and of extracorporeal)The main group of agents, protective agents, ointments, stimulator of tissue repair - alflutop intramuscularly scheme, blockade with glucocorticosteroids)
Khron. periostat arthritis in the shoulder joint aggravation. Severe arthralgia.Khron. fileburst. The expressed painful syndrome.Khron. periastron artrit shoulder aggravation. Severe arthralgia.Khron. fileburst. The expressed painful syndrome.
The pain intensity before therapy++++++++++++++++
Pain, symptoms of relapse after treatment:the
After 1 year--++++
After 3 years+-++++++
After 5 years++++++++
Complications during therapy:
Exacerbation of chronic diseases of the gastrointestinal tract, and others;--+++++
Temporary worsening of the underlying disease for the entire period of the treatment+++++++
Quality of life after treatment++++++++++
Annual financial the cost of treatment ++++++++

Table 3
Indicators/ Signs on a scaleThe control group (the proposed method of treatment - the author's comprehensive inside, periarticular, vnutrikvartalny, paravertebral blockade and of extracorporeal)The main group of agents, protective agents, ointments, stimulator of tissue repair - alflutop intramuscularly scheme, blockade with glucocorticosteroids)
Coxarthrosis 2 tbsp., aggravation. Severe arthralgia.Khron. outside epicondylitis of the humerus. The expressed painful syndrome.Coxarthrosis 2 tbsp., aggravation. Severe arthralgia.Khron. outside epicondylitis of the humerus. The expressed painful syndrome.
The pain intensity before therapy++++++++++++++++
Pain, symptoms recid the VA after treatment:
After 1 year+-++++
After 3 years+-++++++
After 5 years+++++++++
Complications during therapy:
Exacerbation of chronic diseases of the gastrointestinal tract, and others;--+++++
Temporary worsening of the underlying disease for the entire period of the treatment+++++++
Quality of life after treatment++++++++ ++
The annual financial cost of treatment++++++++

The proposed method of treatment is as follows: previously, following the rules of asepsis and antisepsis, dvadtsatimillimetrovym syringe consistently impose the following dosage forms (in this case, the decision of a doctor quantitative composition the proposed blockade picked individually, depending on the disease stage and severity of pain, inflammation):

glucosamine with solvent (trade name "don" - 3.0 ml);

stimulants tissue repair and regeneration: chondroitin sulfate

- 2.0 ml (trade name "Chondrogen", or "Mucosal", or "Chongryon"), "Alflutop" - 2.0 ml, "Actovegin - 4-5,0 ml;

- glucocorticosteroid (trade name "Depo-medrol" - 1,0-2,0 ml at a concentration of 40 mg/ml, or Diprospan" - 1,0-2,0 ml at a concentration of 7 mg/ml, or Metypred" - 1,0-2,0 ml at a concentration of 62.5 mg/ml);

- vitamins B1, B6, B12 for injection (trade name "Combilift" - 2.0 ml, or Neurobion" - 3.0 ml, or Milgamma" - 2.0 ml);

- 95% ethyl alcohol or 70% - 2,0-4,0 ml

In the case of RSD ODE to the patient after the treatment space siege three times antiseptic, complying with the rules is of asepsis and antisepsis, pre obezbolit if necessary, a local anesthetic to the area of the blockade, in the region of the pathological focus its trigger point enter the author's complex injectable composition. Gently slowly perform this blockade. Remove the needle from the syringe handle the injection site with an antiseptic solution and tightly on his stick a little sterile clamp type "Fixator" or "Cosmopol". Then within the first few minutes immediately begin the session shock wave therapy directly to the disease site and adjacent to it segments. When this is used, for example, the apparatus MASTERPULS MR", STORZ MEDICAL FG (Serial number: BS.1324; Model: 2009 IPX1). The exposure parameters depend on each clinical situation and vary in the following ranges: pressure from 1.2 to 4.0 bar, the frequency is from 7 to 12 Hz, the total number of strokes on one area (the hearth and segments) from 8000 to 14000 shock. On the day of injection and session of the TVC, the patient should be observed protective mode. Next, the blockade and of extracorporeal repeat 1 time in 7-10 days. The total number of procedures varies from 1 to 6 depending on the indications of the doctor's appointment, for example: 1-2 injections and session - it's a small course of therapy, 3-4 blockade and session - the average course of therapy, 5-6 blocks and sessions - the full course of therapy. The qualitative composition of the proposed insertion of the mixture remains the same, as stated is use, varies quantitative relationship of drugs in it. In accordance with the invention a mixture of drugs injected into the pathological focus, and then immediately hold the session of the TVC.

The proposed method of complex treatment used in deforming arthrosis of the joints, chronic pain syndromes after injuries and trauma surgery, with contractures of joints, tendinopathy, insertinto and other degenerative-dystrophic diseases of the musculoskeletal system.

Example 1. Patient F., 15.07.1935 year of birth, outpatient map No. 148, was in outpatient treatment with 27.07.2009 on 10.08.2009, with a diagnosis of "deforming osteoarthritis of the left knee Charter 2-3 tbsp., aggravation. Severe arthralgia" (MRI from 4.07.2009 year: Mr-signs of degenerative meniscus degenerative changes cruciate and collateral ligaments. Unsharp marked synovitis. Popliteal cyst Becker.). Sick for 30 years, at the first appointment was with a cane - additional support. Took a course of therapy on the proposed method. The method consisted of the following: the patient has to lie down on the couch on his back, below the knee put the roller in such a way that the lower limb was bent at the knee at an angle of 170 degrees. On the lateral surface of the left knee, after processing the TCI field of the siege and advanced local anesthesia introduced into the joint cavity gently syringe with a prepared mixture of drugs: "the don" - 3.0 ml, Alflutop" - 2.0 ml, Mucosal" - 2.0 ml, "Actovegin - 4,0 ml, "Depo-medrol" - 2.0 ml (80 mg), Combilift" - 2.0 ml, ethyl alcohol 70%-4,0 Jr. Pulled the needle from the syringe, handled the injection site with an antiseptic solution and tightly sealed point vcol needle a little sterile clamp type "Fixator". Then within the first few minutes started the session shock wave therapy directly on the knee and the thigh and Shin of the left lower extremity. Used machine "MASTERPULS MR", STORZ MEDICAL FG (Serial number: BS.1324; Model: 2009 IPX1) and the following parameters impact: 1,2-2,0-4,0 bar, 7-12 Hz, 14,000 strokes per session. On the day of injection and session of the TVC, the patient kept a protective mode, side effects were noted. In total 3 blockade and session VIPs every 7 days. For the treatment of pain syndrome was arrested by 90-95%, in the last session the patient without additional support. Long-term results (4 years) satisfactory, no complaints.

Example 2. Patient B., 11.12.1966 year of birth, outpatient map No. 486, was in outpatient treatment with 27.07.2008, 24.08.2008, with a diagnosis of "chronic humeroscapular periarteritis right aggravation. Calcification of the tendon of the supraspinatus muscle on the right. Pronounced the initial pain syndrome". Considers herself a patient in the course of 6-7 years. Complaints characteristic crunch when the lead hand, restricting her movements and pain during movements of the shoulder joint. The patient has long been treated conservatively (ointments, NSAIDs, blockade with diprospan), positive results are minor and temporary. Conducted therapy under the proposed method: position the patient sitting on a chair (the shoulders dangle), sequentially in each trigger painful area paraartikulyarnye tissues in the shoulder joint following the rules of asepsis and antisepsis, introduced a medicinal mixture of the following composition: Dona - 3.0 ml, Alflutop" - 2.0 ml, Chondrogard" - 2.0 ml, "Actovegin - 5.0 ml, "Diprospan" - 1.0 ml (7 mg), Neurobion" - 3.0 ml, 95%ethyl alcohol -2,0 ml Directly after injection immediately held a session of the TVC apparatus "MASTERPULS MR", STORZ MEDICAL FG (Serial number: BS.1324; Model: 2009 IPX1). The exposure parameters are the following: 1,2-3,0-4,0 bar, 8-12 Hz, 8000 strokes per session. On the day of injection and session of the TVC, the patient kept a protective mode, it was observed a temporary increase of pain after the first session, then with each subsequent session came a gradual improvement. In total 5 blocks and sessions of the TVC with an interval of 7 days. For the treatment of pain syndrome was arrested in full, the amount of movement in the shoulder joint increased. The patient is assigned to physical therapy, dozorova the Naya soft muscle development zone of the upper limb. The control of the state after 5 years: the patient no complaints.

The method of treatment of degenerative-dystrophic diseases of the musculoskeletal system, which includes the use of drugs stimulants regeneration and repair of tissues, characterized in that in the region of the pathologically changed hearth introduce 16-21 ml of the composition consisting of drugs: glucosamine sulfate Dona - 3.0 ml, and chondroitin sulfate Chondrogard", or "Mucosal", or "Chongryon" - 2.0 ml, and Alflutop" - 2.0 ml, and Actovegin - 4,0-5,0 ml, and glucocorticosteroids - "Depo-medrol" - 1,0-2,0 ml at a concentration of 40 mg/ml, or Diprospan" - 1,0-2,0 at a concentration of 7 mg/ml, or Metypred" - 1,0-2,0 at a concentration of 62.5 mg/ml, and vitamins B1, B6, B12 - Combilift" - 2.0 ml, or Milgamma" - 2.0 ml, or Neurobion" - 3.0 ml, and 95% ethyl alcohol or 70%-2,0-4,0 ml, and directly after that the area of the pathological lesion and adjacent thereto segments exercise session shock wave therapy in the following mode: pressure - 1,2-4,0 bar, frequency - 7-12 Hz, number of shock - 8000-14000 within 20-40 minutes, and complex procedures carried out course 1-6 times at intervals of 7-10 days.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of general formula [1] or their pharmaceutically acceptable salts, which possess properties of an inhibitor of the JAK2 thyrokinase activity. In general formula radicals are selected from group (I) or (II). In group (I) X represents CH or N; R1 represents a halogen atom and R2 represents H, a halogen atom, CN, or is selected from the groups of formulas

,

or a group -ORP or 5-6-membered heteroaryl, containing 1-4 nitrogen atoms and optionally additionally containing an oxygen or sulphur atom or containing an oxygen atom as a heteroatom, optionally substituted; or (II) X represents -CRA; and RA represents a group of formula , RB represents (a) amino, optionally substituted with one or two groups, selected from the group, consisting of C1-6alkyl, C3-6cycloalkyl, (C3-6cycloalkyl)C1-6alkyl and C1-3alcoxyC1-3alkyl, (b) C1-3alcoxy, (c) hydroxy or (d) a 5-6-membered saturated cyclic amino group, which additionally can contain a heteroatom, selected from an oxygen atom; R1 represents a halogen atom and R2 represents H; R3 -R5 have values given above. Other values of the radicals are given in the invention formula.

EFFECT: compounds can be applied for the prevention or treatment of cancer, for instance hematologic cancer disease or a solid form of cancer, inflammatory disorder, for instance, rheumatoid arthritis, inflammatory intestinal disease, osteoporosis or multiple sclerosis and angiopathy, for instance, pulmonary hypertension, arteriosclerosis, aneurism or varicose veins.

14 cl, 19 tbl, 234 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises intravenous injection of 3-5.5% aqueous solution of lithium chloride based on 2.5-3.5 mmol/kg of animal body weight, and additionally subcutaneously 10-30% aqueous solution of polyethylene glycol-4000 based on 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: increased efficiency and simplification of the method.

4 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises administering the medicinal product, and the medicinal product is used as 10-30% aqueous solution of polyethylene glycol-4000, which is administered subcutaneously in an amount of 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: improvement of efficiency of the method.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I), possessing an activity with respect to cytokines, versions of based on them pharmaceutical compositions and their application. Formula (I) compounds can be applied for treatment or prevention asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis or gouty arthritis. In general formula (I) L is selected from the group, consisting of -C(O)-, -CH2-, Ar1 represents a mono-, di- or trisubstituted phenyl ring, where substituents are independently selected from the group, consisting of a halogen and -C1-4alkyl; Ar2 represents an optionally substituted thiadiazolyl ring, where the substituent represents -C1-4alkyl, -C3-5cycloalkyl, -methylcyclopropyl, phenyl or a 5- or 6-membered monocyclic heteroaromatic ring or a bicyclic heteroaromatic ring with 9 or 10 atoms, with the said heteroaromatic ring containing 1, 2 or 3 heteroatoms, selected from the group, consisting of S, O and N, where the said phenyl or heteroaromatic ring is optionally mono- or disubstituted with substituents, independently selected from the group, consisting of a halogen, -C1-6alkyl, optionally substituted with 1-4 fluorine atoms, -O-C1-6alkyl, -CF3 and oxo.

EFFECT: increased efficiency of the application of the compounds.

16 cl, 1 tbl, 46 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating patients with epicondylitis. That is ensured by applying a complex of measures, in particular a restraint of motions in the involved segment, physiotherapy and drug treatment. A pain syndrome is pre-evaluated by a visual analogue scale (VAS). A proximal forearm is immobilised with an epicondylic bandage in the daytime for 7-10 days in sportsmen, and for 2-3 weeks in common patients. Therapeutic exercises (TE) are prescribed from the first day of treatment. The first part of TE consisting of isometric and static exercises aiming at strengthening arm muscles is done before noon. The second part of TE comprising relaxing exercises is performed in the late afternoon or after any physical loads. The patient continues with the therapeutic exercises after the bandage is removed and to be used for professional or sports loads only. Electric stimulation is conducted daily for 7-10 days with using TENS apparatus or its analogues generating electrical signals covering the enthesis and the involved forearm muscles. Arthrofoon is administered with underlying electric stimulation. If the pain syndrome value according to the VAS is less than 4 points, the preparation is administered as a monotherapy in a dose of 4 weeks a day for three months. If the pain syndrome according to the VAS is more than 4 points, Arthrofoon is administered in a dose of 8 tablets a day in a combination with a selective non-steroid anti-inflammatory preparation in a therapeutic dose for no more than 10 days. The therapeutic regimen also contains Sirdalud 2-4 mg one hour before bedtime for 2 weeks. There are also administered vasodilators improving microcirculation of the involved segment, intramuscularly for 10 days. The therapeutic complex is also added with Milgamma B 2 ml, 5 injections, and another 5 injections triduan. Wobenzyme is administered for 3-4 weeks. Calcemine or Calcemine-advance, the preparations of calcium are administered for six months. The therapeutic course according to the presented regimen is repeated half a year later. The physical exercising for the arm muscles strengthening are to be further done two or three times a week on the average for min. 30 minutes for the life term if suffering high loads or doing any top-class sports for the purpose of maintaining the forearm tonus. The segment of interest is fixed with an orthesis when suffering a load. The therapy with the TENS or similar apparatus of the forearm muscles of interest and the enthesis follow a pronounced load 2-3 hours before bedtime and shall be accompanied with a session of relaxing exercises.

EFFECT: method provides the evident and stable clinical effect characterised by the complete recurrence-free recovery by the physical restoration of the tissue structure within the inflammation with the high quality of life and a surgical intervention avoided.

1 dwg, 2 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposes a molecule that is specifically combined with CD37 and that contains the following from N-end to C-end: (a) CD37-specific scFV containing the following from N-end to C-end: (i) humanized variable region of a heavy chain, which contains CDR1 GYNMN, CDR2 NIDPYYGGTTYNRKFKG and CDR3 SVGPFDS, (ii) linker having 5 to 30 aminoacids inclusive, and (iii) humanized variable region of an easy chain containing CDR1 RASENVYSYLA, CDR2 FAKTLAE and CDR3 QHHSDNPWT; (b) a link region; and (c) immunoglobulin regions CH2 and CH3. The following is described: The following is described: nucleic acid coding the above binding molecule; an expression vector containing the above nucleic acid; and a host cell for production of a binding molecule, which contains the above vector. The invention proposes use of the above binding molecule to obtain a medicinal agent to reduce the number of B-cells, treatment of a disease or an illness, which is related to abnormal activity of B-cells. Besides, the invention describes compositions containing effective number of the above binding molecule to reduce the number of B-cells, treatment of a disease or an illness related to abnormal activity of B-cells.

EFFECT: invention allows obtaining scFV molecule binding CD37, having orientation of variable regions VHVL, with high yield and efficiency in comparison to scFV molecule against CD37, which has orientation of variable regions VLVH.

31 cl, 17 dwg, 13 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to biotechnology and represents a pharmaceutical composition applicable for treating a rheumatic disease and containing the humanised anti-CD4 antibody able to activate CD4+CD25+ regulatory T-cells, and methotrexat. The present invention also discloses a kit and a method of treating the rheumatic disease with using the above pharmaceutical combination and the above kit.

EFFECT: invention enables implementing more effective methods of treating the rheumatic diseases, including rheumatoid arthritis.

57 cl, 8 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a biological material containing: a) a liquid carrier containing a viscous solution containing at least one natural and/or semisynthetic polysaccharide and having a dynamic viscosity measured at 20°C and at shear rate D=350 s-1, within the range of 100 to 250 centipoise and/or kinematic viscosity within the range of 99 to 248 centistokes (measured in the same environment); b) a autologous or heterologous mesenchymal cell culture and/or c) platelet rich blood product.

EFFECT: material in form of viscous liquid is particularly applicable for the therapy of osteoarthritis, ligament injuries and administered intra-articularly, intradermally or applied in situ without change of the properties of the mesenchymal stem cells and/or its platelets.

11 cl, 5 ex

FIELD: medicine.

SUBSTANCE: method involves a preclinical electroneuromyography (ENMG) of the neuromuscular apparatus of injured and intact lower extremities to measure a muscle response amplitude - an M-response. The findings are recorded. Starting from the second postoperative day, in the course of the drug-induced neuroprotective treatment and therapeutic exercises, the following therapy is additionally performed for 10-15 days. If the injured M-response amplitude is below 4.0 mV, while the respective intact value is more than 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity is performed. If the injured M-response amplitude is more than 4.0 mV, while the respective intact value is below 4.0 mV, the stimulating passive physical treatment covering the intact extremity is performed. If the M-response amplitude of the injured and intact extremities is below 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity and the stimulating passive physical treatment covering the intact extremity are performed. Three and six months following the surgical management, the repeated ENMG of the neuromuscular apparatus of the lower extremities to measure the M-response amplitude. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity three months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity six months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical functional treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed by walking electrical stimulation of the hip and shin.

EFFECT: method reduces the length of treatment and increases its effectiveness with decreasing a percentage of neurological complications by performing the individual complex exposure on the neuromuscular apparatus of the lower extremities taking into account the ENMG findings of the neuromuscular apparatus of the lower extremities.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I), wherein A means morpholinyl, 1,4-oxazepamyl, piperidinyl, pyrrolidinyl or azetidinyl which is bound to N; R1 means C1-C6-alkyl group; R2 means bicyclic aryl group specified in 1H-indolyl, 1H-pyrrolo[3,2-b]pyridyl, quinolyl, naphthyl, 1H-pyrrolo[2,3-b]pyridyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, benzo[b]thiophenyl, imidazo[1,2-a]pyridyl, benzo[b]thiazolyl, 5H-pyrrolol[2,3-b]pyrazinyl and quinoxalinyl which can be substituted by R4; R3 means hydrogen or halogen atom; R4 means C1-C6-alkyl group, C1-C6-halogenalkyl group, OR1A, halogen, -(CH2)aOH, CN, NHCOR1A, SO2R1A or NHSO2R1A; R5 means C1-C6-alkyl group, -(CH2)aOH, -(CH2)aOR1B, halogen or CONH2; provided p is a plural number, R5 can be identical or different, or R5 can be combined with another R5; each of R1A and R1B independently means C1-C6-alkyl group; a is equal to 0, 1 or 2; n is equal to 1 or 2; p is equal to 0, 1, 2, 3, 4 or 5. Besides, the invention refers to intermediate compounds of formulas (IA) and (IB) for preparing the compounds of formula (I), to a preventive or therapeutic agent containing the compounds of formula (I), pharmaceutical compositions, using the compounds of formula (I) and to a method for preventing or treating diseases.

EFFECT: compounds of formula (I) as selective 5-HT2B receptor antagonists.

11 cl, 1 dwg, 18 tbl, 88 ex

FIELD: medicine.

SUBSTANCE: method involves a course of 5-7 pulse ultrasonic procedures having an intensity of 0.2-0.4 W/cm2 of 5-7 minutes daily. That is combined with enzyme therapy with Longidaza 3,000 units 2 times a week for 1 month. Besides, Trilon B rectal suppositories 1,000 mg and Dimexidum 200 mg are administered daily for the night for 3 months. The bacteria are detected by a microscopic and microbiologic examination of ejaculate that is followed by a 4-6-week antibacterial therapy by administering an antibacterial preparation taking into account the microflora sensitivity.

EFFECT: such implementation of the method provides removing the prostate stones or decreasing the number thereof, reducing a probability of the inflammatory process in the prostate, ensuring a differentiated therapeutic approach by detecting the group of patients whom the antibacterial therapy is indicated to.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.

EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.

3 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves the combined exposure to ultrasound and electric current on a projection of the bladder. The ultrasonic exposure is carried out at the intensity of 0.2-0.4 W/cm2, frequency of 1 to 3 MHz. The electric pulse exposure involves amplitude modulated current in the frequency range of 100-250 Hz, at a basic frequency of 5-8 kHz for 10 minutes. The therapeutic course involves 8-12 procedures.

EFFECT: method prevents such complications of the bladder dysfunctions, as vesicoureteral reflux, chronic inflammatory renal and urinary diseases.

1 ex

FIELD: medicine.

SUBSTANCE: palatal tonsils are daily sanitated with antibacterial preparations selected in accordance with the bacteriological examination of oral smears for pathogenic microflora and antibiotic sensitivity with the tonsil lacunae washed for 10 days. Pre-anaesthesia is followed by the tonsil lacunae exposure to an ultrasonic disintegrator at a depth of a probe working area at an amplitude of 23-26 mc every second day for 5 days. That is followed by paratonsil administration of polyoxidonium in an adult dose of 6 mg every second day for 5 days; the therapeutic course is performed once a year.

EFFECT: method enables higher clinical effectiveness in chronic tonsillitis.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: placenta hydrolyzate 1 ml mixed with lanolin 30 g before the procedure is applied on an anterior abdominal wall of a patient lying on his/her back in the projection of adhesions. That is followed by phonophoresis generated by UZT-1.07F ultrasonic therapeutic apparatus and sounded by an emitter of the diameter of 4 cm of the intensity of 0.4-0.6 W/cm2. The exposure mode is continuous; an emitter velocity is 1-1.5 cm/sec. The length of procedure is 5-7 minutes. The therapeutic course is 10 procedures.

EFFECT: reduced progression of abdominal adhesions and their manifestations by evident anti-inflammatory effect, reduced pain syndrome, higher adaptive body reserves.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: before the implantation, a demineralised bone graft (DBG) is kept for 2 hours in 0.9% chloride solution at room temperature. Thereafter, the DBG is exposed for 10 minutes to ultrasound at frequency 44±4.4 kHz and vibrational amplitude 30 to 50 mcm in 0.9% sodium chloride solution heated to 36°C.

EFFECT: method enables accelerating the repair processes in grafting a fragment of the demineralised bone graft of the pre-set shape in experimental animals and increasing substantially post-grafting osteogenesis rate in a segment of a skull flat bone.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to prevention of purulent-septic inflammatory complications in obstetric patients of a high infectious risk group. A device comprises an ultrasonic generator with a monitor control, a piezoceramic radiator with a terminal wave guide and an intravenous medication system with a control valve, a pivotally connected system of equally spaced support nuts, supplementary ultrasonic generators with monitor controls and piezoceramic radiators built into the nuts; with a quantity of the piezoceramic radiators matching a quantity of the nuts laid on a spacer, a programmed microcontroller and an indication panel. The piezoceramic radiators are fixed on the support nuts of the pivotally connected systems, flow through spacer holes and are connected to outputs of the respective ultrasonic generators the monitor controls of which are connected to matched outputs of the programmed microcontroller which are simultaneously connected to matched inputs of the indication pane and the control valve of the intravenous medication system.

EFFECT: providing individual spatial characteristic of the effect and higher reliability.

3 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to ultrasound therapeutic apparatuses. An ultrasonic transducer contains at least one ultrasonic radiating element with ultrasonic wave front sets radiated by the element representing spherical surfaces of the same radius, while the ultrasonic radiating element performs a function of ultrasound reflection and forms a spherical resonant cavity. If using more than one ultrasonic radiating element, they are configured to form a combined spherical resonant cavity. An internal space of the spherical resonant cavity is shaped as a full spherical envelope or a truncated spherical envelope with a sphere centre inside, while the ultrasonic waves generated by at least one ultrasonic radiating element are focused in the area which comprises the sphere centre of the spherical resonant cavity.

EFFECT: using the invention provides an ultrasonic focus energy gain, as well as eliminated working frequency influence of an ultrasonic source.

15 cl, 11 dwg

FIELD: medicine.

SUBSTANCE: area of inflammation is exposed to ultrasound generated by the Sonoca 185 apparatus. The exposure power gradually grows within the range of 20 to 40-80 W depending on age. The palatal tonsils are alternately sanitised with octenisept dissolved in 0.9% sodium chloride in a ratio 1:8 with an octenisept flow rate gradually increasing within the range from 20 to 180 ml/s, an exposure time of 2-5 seconds for 3-5 minutes. The therapeutic course is 8-10 sessions, either daily or every second day.

EFFECT: method involves the integrated effect of ultrasound and antiseptic on the oropharyngeal mucosa in the developed regimen that enables providing the higher therapeutic effectiveness, including that in children suffering from chronic tonsillitis, reducing a probability of complications, improving an acceptability of presented therapy.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to energy transmission systems. The energy transmission system involves an energy source for ultrasonic energy supply into a circumferential region adjoining a patient's blood vessel with a circumferential nerve plexus found within the above region. The energy source is configured to use the blood vessel as a support point for energy supply to the nerves surrounding the blood vessel, and for ultrasonic energy supply for generating an annular region of a nerve inhibition around the blood vessel with the annular region arranged along the length of the blood vessel.

EFFECT: using the invention enables more effective targeted energy supply.

22 cl, 30 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to a method of pantohematogen production. The method of the pantohematogen production includes sampling blood six times from June to November from culled stags, blood freezing; in the process of production the defrosted blood is homogenised and mixed with sugar syrup, fruit essence and ascorbic acid, the mixture is pasteurised and a preservative "Citrosept grapefruit" is introduced under certain conditions.

EFFECT: method possesses the expressed general toning and stimulating action.

4 tbl

Up!